A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects (clinicaltrials.gov) - Apr 18, 2023 - P1 | N=18 | Not yet recruiting | Sponsor: Endeavor Biomedicines, Inc.
New P1 trial • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases
|